Skip to content

Author

Yu-Wei Chen

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

19 Dissecting ARNT Expression Patterns in RCC and Association with Outcomes

Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...

Yu-Wei Chen, S. Nazari, A. Elliott et al. · 0 citations
Open access Sep 2026

23 PRISM: Phase 1b of Retifanlimab and Ruxolitinib in Solid Malignancies Progressing on Prior Checkpoint Inhibition (NCT07219576)

Abstract Background Despite improved outcomes with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC), most patients develop resistance. Preclinical data demonstrate that Janus kinase inhibition (...

Rana Mckay, L.-J. Wei, Yu-Wei Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.